RA
BLUE

Royce & Associates’s bluebird bio BLUE Stock Holding History

Royce & Associates’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-463
Closed -$324K – 1003
2020
Q3 		$324K Sell
463
-1,467
-76% -$1.14M ﹤0.01% 894
2020
Q2 		$1.53M Buy
1,930
+463
+32% +$349K 0.02% 720
2020
Q1 		$873K Hold
1,467
– – 0.01% 755
2019
Q4 		$1.67M Buy
+1,467
New +$1.59M 0.01% 729
2018
Q4 		– Sell
-772
Closed -$1.46M – 1151
2018
Q3 		$1.46M Hold
772
– – 0.01% 873
2018
Q2 		$1.57M Buy
+772
New +$1.76M 0.01% 883

Other funds holding BLUE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Royce & Associates's BLUE Position: Q4 2020 in Review

Royce & Associates sold out of bluebird bio (BLUE) in Q4 2020, closing a stake of 463 shares — an estimated $324K sold.

Royce & Associates first reported a position in BLUE in Q2 2018 and held it in 6 quarters. The position peaked at $1.67M in Q4 2019. 262 funds tracked by Wall St. Rank hold BLUE as of Q4 2020.

  • Royce & Associates reported no remaining bluebird bio position as of Q4 2020 after selling out during the quarter.
  • Royce & Associates sold 463 bluebird bio shares in Q4 2020, an estimated $324K.
  • Royce & Associates first reported a position in bluebird bio in Q2 2018 and held it in 6 quarters.
  • Royce & Associates's bluebird bio position peaked at $1.67M in Q4 2019.
  • 262 funds tracked by Wall St. Rank held bluebird bio as of Q4 2020.

Based on Royce & Associates's 13F filing for Q4 2020, filed 8 Feb 2021.